Access Gets Rewritten: How August 2026 Redrew Patient Access Without the Patients

CMS closed the comment period on the permanent Medicare Drug Price Negotiation Program rules on August 17 under CMS-4215-P. Biopharma groups including PhRMA objected to how CMS would define eligible drugs, especially the proposed fixed-combination policy. Oncology groups including NCODA fought the combination-product rules and hospitals led by AHA concentrated on 340B duplicate discounts and rebate-style MFP effectuation, and almost nobody filed on behalf of the people taking the drugs.

Hannah Garden-Monheit, the former FTC policy director, published a paper calling for a statutory ban on prior authorization as insurers practice it, with a structural fix that prohibits common ownership between an insurer and the company adjudicating its denials. She wrote it after UnitedHealthcare denied her father a post-amputation rehabilitation stay and the appeal never resolved. Every hub services model and time-to-therapy forecast in commercial planning assumes prior authorization survives intact.

HRSA advanced its revised 340B Rebate Model Pilot over sustained hospital objection. Manufacturer applications closed August 24 with approvals expected by September 24, and rebates would replace upfront discounts on CMS selected drugs starting January 1, 2027, against an administrative cost estimate held at 523 million dollars. Community health centers fund case managers, transportation, and refill outreach out of the cash flow an upfront discount provides.

The Senate HELP Committee advanced a 35 dollar monthly insulin cap for privately insured patients by a vote of 17 to 5, with six Republicans joining every Democrat and a 10-state pilot attached to reach uninsured patients at the same price. The bill landed on the Senate Legislative Calendar on August 7 as S.4189, Calendar No. 552. It had not received a floor vote as of August 30.

A court rejected the bid by 26 states to delay the final Medicaid work requirements rule. Verification paperwork rather than actual eligibility will drive most of the coverage loss, which puts renewal navigation squarely on advocacy organizations in every affected state.

The first CMS prior authorization transparency data arrived, and plans reported request volume without reporting which claims they denied, for whom, or on what clinical basis. Standard denial rates for 2025 ran 12 percent in Medicare Advantage, 14 percent in Medicaid managed care, and 18 percent in the ACA Marketplace. Partial transparency lets a plan claim compliance while the denial pattern stays invisible to the patients living inside it.

Mississippi began promoting short-term limited duration plans as a marketplace alternative while premiums spike. Those plans exclude pre-existing conditions and cap benefits, which sorts the sickest enrollees out of comprehensive coverage by design and shifts their cost onto providers and families.

Researchers at Johns Hopkins and AEI reviewed more than two million first-time fills in JAMA and found 32 percent of initial attempts for single-source brand drugs rejected on formulary grounds, split between 14.8 percent formulary exclusions and 17.2 percent prior authorization or step therapy. Among those rejected attempts, 48.4 percent were never followed by a fill of the prescribed drug or anything else in the same therapeutic class within 90 days. The prescription did not get switched. It stopped.

Health Affairs analyzed 59,717 patients across 5,008 treatment sites and found markups over acquisition cost for one infused biologic averaging 173 percent at 340B-eligible hospitals, 78 percent at hospitals without eligibility, and 16 percent at community physician practices. Annual insurer-reimbursed revenue per patient ran 102,680 dollars, 67,825 dollars, and 3,094 dollars across those same three settings. One molecule and one diagnosis produced three different economies, decided by the address on the infusion order.

KFF read the 2027 rate filings across all 50 states and the District of Columbia and found ACA Marketplace insurers seeking a median 15 percent increase after last year finalized at 20 percent, compounding to roughly 38 percent across two years. Nearly 300 insurers asked for a median 14 percent increase in the small group market, where employers carry the least leverage and the fewest plan design options.

The National Alliance of Healthcare Purchaser Coalitions surveyed 408 employers and found 46 percent now using a pharmacy benefit manager outside CVS Caremark, Optum Rx, and Express Scripts, up from 37 percent last year. Of those still with a big three PBM, 56 percent are considering a change within three years while projecting a 7.7 percent cost increase. Alliance CEO Shawn Gremminger names the two terms buyers now treat as decisive: access to their own claims data, and no spread pricing.

The Business Group on Health found employers no longer treating cost growth as a line item to manage, projecting a median 9.2 percent increase for 2027 and roughly 8 percent after benefit design changes. When plan sponsors start asking whether to offer coverage at all, benefit redesign becomes the single most consequential room in healthcare, and almost no patient organization sits in it.

Employer increases are moving onto workers through deductibles, premium share, and narrower networks, with Aon estimating workplace-covered Americans will spend an average 5,297 dollars this year on premiums plus out-of-pocket costs, 388 dollars above 2025. Cost shifting is the quiet mechanism that converts a corporate budget problem into a household access problem.

The UNC Sheps Center evaluated more than 31,000 enrollees in North Carolina Healthy Opportunities Pilots from 2022 through late 2024 and found net savings of 164 dollars per member per month after all service and overhead costs, with fewer emergency department visits, fewer admissions, and nearly 90 percent of participants reporting improved health. Legislators built the pilots in 2018 under a Democratic governor, a Republican legislature, and the first Trump administration, then voted in July 2026 to continue them. Former state health secretaries Mandy Cohen and Kody Kinsley now want Congress to codify a permanent state pathway.

Nine years ago the Center for Scientific Integrity gave the American Diabetes Association an award for defending a research integrity finding against a lawsuit, and on July 31 those same writers published a STAT First Opinion arguing the organization reversed course and owes accountability for a controversy of its own. That column is an argument rather than a research finding. As of August 30 the ADA had issued no public reply, and its June 10 apology and late-July request for patience address the Scientific Sessions rather than this column.

Nearly half of corporately employed physicians report feeling pressured to prioritize patient volume over care quality, and 63 percent say employer policies make outside referrals difficult. When the clinician in the room names the conflict, the advocacy argument stops sounding adversarial and starts reading as corroboration.

A heart transplant survivor obtained her immunosuppressant only after a viral post drew public attention, with Elevance dropping coverage for off-label everolimus and then restoring it at 1,000 dollars per 90-day supply instead of 180 dollars. One patient with a platform received what the appeals process failed to deliver. Every organization applauding that outcome should count the patients without a platform.

New research found counties with a 340B hospital rose 29 percent and participating hospitals rose 35 percent between 2015 and 2024, yet 64 percent of newly participating nonprofit counties ranked as socioeconomically advantaged. Organizations defending 340B on principle now need evidence, because the critics arrived with data this month.

Federal regulators convened closed-door sessions with industry, researchers, and lobbyists on clinical AI oversight. The rules that will govern automated clinical decisions are taking shape in rooms with no patient representation in them, which is the same failure the Medicare negotiation docket produced two weeks earlier.

Epic launched instant prior authorization checks at four health systems using an HL7 FHIR-based interface, currently covering UnitedHealthcare, CVS Aetna, and Network Health with 16 additional payers testing. Real-time authorization removes days from the approval cycle, and automation speeds approvals and denials with equal efficiency. The governing criteria matter far more than the response time.

Moderna and Merck reported that their individualized mRNA cancer vaccine met its endpoints in a 1,137-participant adjuvant melanoma trial, extending both recurrence-free and distant metastasis-free survival. A therapy manufactured one dose per patient raises turnaround, site-of-care, and reimbursement questions that no existing formulary structure has answered.

Roche and Eli Lilly won FDA clearance for a single-biomarker Alzheimer blood test that identifies amyloid buildup earlier and uses the same validated cutoffs in primary care and specialty settings. Diagnostic volume will arrive faster than treatment capacity, producing informed patients with nowhere to go unless navigation gets built first.

The FDA approved a new pancreatic cancer drug priced at 39,800 dollars a month before rebates, arriving after more than 2,000 patients received it free through expanded access since May. Those families now enter the coverage system, which makes approval the opening of the access fight rather than the end of it.

Take the free Advocacy Influence Diagnostic at aid.elavay.com to evaluate your advocacy function's influence and get a real understanding of its impact within your organization.

Find every source cited in this brief, and the other articles our CEO, Matt Toresco, found valuable last month, at intelligence.archo.io.

For ELAVAY Intelligence briefings and Archo syndicated research on how patient advocacy organizations evaluate pharma and biotech companies, email [email protected].

The 2025/2026 ELAVAY report is available now, and fielding for the 2026/2027 cycle opens in October, which means inclusion decisions happen before then. To request the findings or schedule a briefing, email Archo at [email protected].

For advocacy strategy consulting or advocacy function training to maximize your team’s engagement and influence, reach Matt directly at [email protected].

Connect with the advocacy community and get access to patient and advocacy resources, check out advocatebridge.org and empwrdpatientfoundation.org.